CVRx, Inc. (NASDAQ:CVRX) Shares Purchased by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust lifted its stake in shares of CVRx, Inc. (NASDAQ:CVRX - Free Report) by 28.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 370,813 shares of the company's stock after purchasing an additional 82,978 shares during the quarter. Emerald Mutual Fund Advisers Trust owned about 1.53% of CVRx worth $4,698,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in shares of CVRx by 10,520.1% in the fourth quarter. JPMorgan Chase & Co. now owns 628,286 shares of the company's stock valued at $7,960,000 after purchasing an additional 622,370 shares in the last quarter. Emerald Advisers LLC raised its position in shares of CVRx by 47.3% in the fourth quarter. Emerald Advisers LLC now owns 593,898 shares of the company's stock valued at $7,525,000 after buying an additional 190,844 shares during the last quarter. Norges Bank acquired a new stake in CVRx during the fourth quarter worth approximately $1,411,000. Trexquant Investment LP grew its stake in CVRx by 292.9% in the 4th quarter. Trexquant Investment LP now owns 102,197 shares of the company's stock worth $1,295,000 after acquiring an additional 76,184 shares during the period. Finally, Tradewinds LLC. acquired a new position in CVRx in the 4th quarter valued at $695,000. Hedge funds and other institutional investors own 75.27% of the company's stock.

CVRx Trading Up 9.1 %

Shares of CVRX stock traded up $0.66 during mid-day trading on Friday, reaching $7.95. The company's stock had a trading volume of 409,464 shares, compared to its average volume of 316,709. The company has a quick ratio of 10.23, a current ratio of 12.06 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $207.15 million, a PE ratio of -2.96 and a beta of 1.34. The company's 50 day simple moving average is $9.87 and its 200-day simple moving average is $12.73. CVRx, Inc. has a 12-month low of $5.81 and a 12-month high of $18.55.

CVRx (NASDAQ:CVRX - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.06). CVRx had a negative return on equity of 93.06% and a negative net margin of 116.91%. On average, research analysts predict that CVRx, Inc. will post -1.91 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CVRX has been the subject of a number of recent analyst reports. Piper Sandler lifted their price objective on CVRx from $16.00 to $20.00 and gave the company an "overweight" rating in a research report on Wednesday, February 5th. Lake Street Capital cut their price objective on shares of CVRx from $19.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday, April 8th. William Blair upgraded shares of CVRx from a "market perform" rating to an "outperform" rating in a report on Tuesday, January 14th. Craig Hallum increased their price target on shares of CVRx from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. Finally, Canaccord Genuity Group lowered their price objective on shares of CVRx from $23.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, April 8th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $17.60.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.